Stockscreener 앱 받기
4.71
0.64%
0.03
전일 마감가:
$4.68
열려 있는:
$4.69
하루 거래량:
85,254
Relative Volume:
0.53
시가총액:
$126.03M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-15.29%
1개월 성능:
-41.64%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$4.52
$4.82
1주일 범위
$4.52
$5.7899
52주 변동 폭
$4.52
$18.79
Conexeu Sciences Inc Stock (CNXU) Company Profile
명칭
Conexeu Sciences Inc
전화
604-315-4722
주소
50 WEST LIBERTY STREET, SUITE 880, RENO
Compare CNXU vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CNXU
Conexeu Sciences Inc
|
4.71 | 125.23M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
520.82 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.41 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,005.47 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.19 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.01 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Conexeu Sciences Inc 주식(CNXU)의 최신 뉴스
Top Conexeu Sciences (CNXU) Competitors 2026 - MarketBeat
CNXU Should I Buy - Intellectia AI
Ambarella Q2 Revenue Rises 12% as Net Loss Narrows Sharply - minichart.com.sg
Investment fund caps Conexeu Sciences (CNXU) stake below 10% - Stock Titan
Near-10% stake in Conexeu (CNXU) tied to warrant cap - Stock Titan
Conexeu Sciences (NASDAQ:CNXU) Shares Down 5.2%Here's What Happened - MarketBeat
A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture - Finansavisen
Conexeu Steps Up Investor Outreach Ahead of Key Regulatory Milestones - TipRanks
Conexeu Sciences Sets September and October 2026 Conference Schedule - The Manila Times
At Nasdaq headquarters, a biotech company will present Sept. 9, then attend two more events. - Stock Titan
Conexeu Sciences (CNXU) pays consultants with $88K in stock - Stock Titan
Here's Why We're Not Too Worried About Conexeu Sciences' (NASDAQ:CNXU) Cash Burn Situation - webull.com
Conexeu Sciences (CNXU) Insider Trading Activity 2026 - MarketBeat
The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts - Eastern Progress
A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It. - The Spec
The Biggest Winners Don't Compete in a Category. They Rewrite It. One Company Is Betting It Can Too. - marketscreener.com
Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration - Moomoo
Jeffrey Sharpe Discloses Investment at Conexeu Sciences Inc. with 5.4% Stake - TradingView
2.3M-share stake in Conexeu Sciences (CNXU) revealed by single investor - Stock Titan
Conexeu (CNXU) director gets $0.001 warrants tied to Nasdaq, FDA goals - Stock Titan
CNXU - Finviz
Conexeu Sciences Inc. (CNXU) BetaZacks.com - Zacks Investment Research
CNXU : Conexeu Sciences Inc. Key Company Details - Zacks Investment Research
Conexeu Sciences (CNXU) Stock Trends and Sentiment 2026 - MarketBeat
Conexeu Sciences (CNXU) investor reports 12.3% stake and warrant-linked shares - Stock Titan
Conexeu Sciences Inc. (CNXU) investor discloses 5.5% stake in Schedule 13G filing - Stock Titan
OnePointTwo Capital Ventures (CNXU) discloses 1.88M-share Conexeu Sciences stake - Stock Titan
One Platform, Five Markets: Insights Into Conexeu Sciences Inc. - SmallCap Asia
The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For - marketscreener.com
Conexeu to Present at 2026 Controversies & Conversations in Laser and Cosmetic Surgery Symposium on the Role of the Extracellular Matrix in Tissue Regeneration - marketscreener.com
Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It - marketscreener.com
Conexeu Highlights ECM-Based Regenerative Platform Ahead of 2026 Aesthetics Symposium - TipRanks
Conexeu to Present at 2026 Controversies & Conversations in Laser & Cosmetic Surgery Symposium on the Role of the Extracellular Matrix in Tissue Regeneration - The Manila Times
Beyond volume: Conexeu to discuss the body's repair process - Stock Titan
Conexeu Sciences Ord Shs (CNXU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GT Biopharma’s TriKE® Program: Pipeline, Progress, & What’s Ahead - SmallCap Asia
Price to earnings forward of Conexeu Sciences Inc. – NASDAQ:CNXU - TradingView
Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One - Investing News Network
Next GLP-1 Billion-Dollar Market: Fireside Chat with Conexeu Sciences CEO Miles Harrison - IPO Edge
Conexeu Sciences (CNXU) investor Michael G. Wright discloses 12.1% ownership stake - Stock Titan
Short Interest in Conexeu Sciences Inc. (NASDAQ:CNXU) Expands By 357.1% - MarketBeat
CNXU|Conexeu Sciences Ord Shs|Price:8.630|Chg%:-1.360 - TradingKey
Conexeu Sciences Inc. Revenue Breakdown – NASDAQ:CNXU - TradingView
Paisley Capital reports 1.8M-share position in Conexeu Sciences Inc. (CNXU) - Stock Titan
David Robert Bogart Net Worth (2026) - GuruFocus
Ana Lucia Bastiani Posner Net Worth (2026) - GuruFocus
Aaron Solomon Farberg Net Worth (2026) - GuruFocus
Jeffrey Nathan Sharpe Net Worth (2026) - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
Conexeu Sciences Inc.Common Stock (CNXU) Stock Price, News, Quote & History - FinancialContent
Breakeven Is Near for Pulsar Group plc (LON:PULS) - simplywall.st
Conexeu Sciences Inc (CNXU) 재무 분석
Conexeu Sciences Inc (CNXU)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.71%
2.84%
자본화:
|
볼륨(24시간):